DE60213958T2 - Aryl-n-cyanoguanidine derivate und deren verwendung - Google Patents

Aryl-n-cyanoguanidine derivate und deren verwendung Download PDF

Info

Publication number
DE60213958T2
DE60213958T2 DE60213958T DE60213958T DE60213958T2 DE 60213958 T2 DE60213958 T2 DE 60213958T2 DE 60213958 T DE60213958 T DE 60213958T DE 60213958 T DE60213958 T DE 60213958T DE 60213958 T2 DE60213958 T2 DE 60213958T2
Authority
DE
Germany
Prior art keywords
substituted
mitochondrial
compound according
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60213958T
Other languages
German (de)
English (en)
Other versions
DE60213958D1 (de
Inventor
Soumitra San Diego GHOSH
R. Tomas San Diego SZABO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Migenix Corp
Original Assignee
Migenix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Migenix Corp filed Critical Migenix Corp
Application granted granted Critical
Publication of DE60213958D1 publication Critical patent/DE60213958D1/de
Publication of DE60213958T2 publication Critical patent/DE60213958T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
DE60213958T 2001-02-27 2002-02-27 Aryl-n-cyanoguanidine derivate und deren verwendung Expired - Fee Related DE60213958T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27236801P 2001-02-27 2001-02-27
US272368P 2001-02-27
PCT/US2002/006717 WO2002068381A2 (en) 2001-02-27 2002-02-27 Aryl-n-cyanoguanidines and methods related thereto

Publications (2)

Publication Number Publication Date
DE60213958D1 DE60213958D1 (de) 2006-09-28
DE60213958T2 true DE60213958T2 (de) 2007-08-30

Family

ID=23039505

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213958T Expired - Fee Related DE60213958T2 (de) 2001-02-27 2002-02-27 Aryl-n-cyanoguanidine derivate und deren verwendung

Country Status (9)

Country Link
US (4) US6562821B2 (https=)
EP (1) EP1377282B1 (https=)
JP (1) JP2004525906A (https=)
AT (1) ATE336237T1 (https=)
AU (1) AU2002254124A1 (https=)
CA (1) CA2475454A1 (https=)
DE (1) DE60213958T2 (https=)
ES (1) ES2271247T3 (https=)
WO (1) WO2002068381A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60213958T2 (de) * 2001-02-27 2007-08-30 Migenix Corp., San Diego Aryl-n-cyanoguanidine derivate und deren verwendung
US7411000B2 (en) * 2001-03-15 2008-08-12 The Scripps Research Institute Process of inhibiting cell death in injured cartilage
US6916813B2 (en) * 2001-12-10 2005-07-12 Bristol-Myers Squibb Co. (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
US7642092B2 (en) * 2003-03-03 2010-01-05 Technion Research & Development Foundation Ltd. Cultured cartilage/bone cells/tissue, method of generating same and uses thereof
EP3747449A4 (en) * 2018-02-02 2021-10-20 Paean Biotechnology Inc. PHARMACEUTICAL COMPOSITION WITH ISOLATED MITOCHONDRIA FOR THE PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265905A (en) 1975-09-30 1981-05-05 Merck & Co., Inc. Method of treating inflammation employing acyl cyanoguanidines
GB8400863D0 (en) * 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
CN1450999A (zh) * 2000-03-31 2003-10-22 辉瑞产品公司 新的哌嗪衍生物
DE60213958T2 (de) * 2001-02-27 2007-08-30 Migenix Corp., San Diego Aryl-n-cyanoguanidine derivate und deren verwendung

Also Published As

Publication number Publication date
US20040067987A1 (en) 2004-04-08
ES2271247T3 (es) 2007-04-16
US20030045556A1 (en) 2003-03-06
EP1377282B1 (en) 2006-08-16
CA2475454A1 (en) 2002-09-06
WO2002068381A2 (en) 2002-09-06
US7230132B2 (en) 2007-06-12
ATE336237T1 (de) 2006-09-15
US6562821B2 (en) 2003-05-13
DE60213958D1 (de) 2006-09-28
AU2002254124A1 (en) 2002-09-12
EP1377282A2 (en) 2004-01-07
WO2002068381A3 (en) 2002-10-31
JP2004525906A (ja) 2004-08-26
US6927218B2 (en) 2005-08-09
US20050182057A1 (en) 2005-08-18
US20080032981A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
DE60218443T2 (de) Jasmonate enthaltende therapeutische zusammensetzungen für die behandlung von krebs
US6268398B1 (en) Compounds and methods for treating mitochondria-associated diseases
DE69815122T2 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
DE69526956T2 (de) Proteinkinase c-inhibitoren zur behandlung von neurologischen erkrankungen
DE602004012279T2 (de) Katecholderivate zur behandlung von krebs
DE69733834T2 (de) Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren
DE69728782T2 (de) Verwendung von no synthase hemmern und fängern von reaktiven sauerstoffsformen zur behandlung von ischämie
DE69935720T2 (de) Diamino-propanol-verbindungen zur behandlung von ischaemien
EP1200831B1 (de) Modulatorische bindungsstelle an kaliumkanälen zum screening
DE60011755T2 (de) Calciumkanalblocker als antikrebsmittel
DE60129518T2 (de) Verwendung von einem Vasopressin-Antagonisten wie Conivaptan zur Herstellung eines Medikaments für die Behandlung der pulmonalen Hypertension
DE69121706T2 (de) O6-benzylierte guanine, guanosine und 2'-deoxyguanosine verbindungen mit o6-alkylguanin-dna-alkyltransferase dezimierter aktivitaet
DE112007003375B4 (de) Imidazolderivate, die Apoptose induzieren, und deren therapeutische Anwendung
US4579869A (en) Substituted [(2,3-dihydro-1-oxo-1H-inden-5-yl)amino]alkanoic acids, their derivatives and their salts
DE60213958T2 (de) Aryl-n-cyanoguanidine derivate und deren verwendung
DE3415805C2 (de) Inhibitoren der Nephrotoxizität von Aminoglykosid-Antibiotika
US9463195B2 (en) Dissolution of amyloid fibrils by flavonoids and other compounds
DE3786256T2 (de) Antifolat-mittel.
US20050233984A1 (en) Composition for preventing or treating degenerative brain diseases comprising a hydrolysate of ginsenosides
DE69935724T2 (de) L-acetylcarnitine als antitumormittel
KR101867779B1 (ko) 피라졸 유도체를 유효성분으로 함유하는 소양증의 예방 또는 치료용 약학적 조성물 및 이를 검출하기 위한 스크리닝 방법
KR101877002B1 (ko) 피라졸 유도체를 유효성분으로 함유하는 소양증의 예방 또는 치료용 약학적 조성물 및 이를 검출하기 위한 스크리닝 방법
DE60008111T2 (de) Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn
DE69214180T2 (de) Verwendung von Bis-(p-Hydroxyphenylthio)methanderivaten zur Hemmung der fortschreitenden Entwicklung von insulinabhängingem Diabetes mellitus
EP1471901B1 (en) Spermidine derivative for the treatment of chronic neurodegenerative diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee